Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Pre-Mkt 02-27 08:29:21 EST

65.90

-4.47

-6.35%

盘前65.70

-0.20-0.30%

08:01 EST

High70.99	Low64.50	Vol1.44M
Open70.00	D1 Closing70.37	Amplitude9.22%
Mkt Cap1.84B	Tradable Cap1.73B	Total Shares27.98M
T/O95.85M	T/O Rate5.50%	Tradable Shares26.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":65.9,"timestamp":1772139600000,"preClose":70.37,"halted":0,"volume":1442400,"hourTrading":{"tag":"盘前","latestPrice":65.7,"preClose":65.9,"latestTime":"08:01 EST","volume":661,"amount":43154.336839999996,"timestamp":1772197267067,"change":-0.2,"changeRate":-0.003035,"amplitude":0.022307},"delay":0,"changeRate":-0.06352138695466816,"floatShares":26240400,"shares":27979500,"eps":-7.899717,"marketStatus":"Pre-Mkt","change":-4.47,"latestTime":"02-27 08:29:21 EST","open":70,"high":70.99,"low":64.5,"amount":95849808.0336,"amplitude":0.092227,"askPrice":66.2,"askSize":4,"bidPrice":62,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-7.899717,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772202600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":65.9,"preHourTrading":{"tag":"盘前","latestPrice":65.7,"preClose":65.9,"latestTime":"08:01 EST","volume":661,"amount":43154.336839999996,"timestamp":1772197267067,"change":-0.2,"changeRate":-0.003035,"amplitude":0.022307},"postHourTrading":{"tag":"盘后","latestPrice":65.12,"preClose":65.9,"latestTime":"19:58 EST","volume":16069,"amount":1058439.3132,"timestamp":1772153931313,"change":-0.78,"changeRate":-0.011836,"amplitude":0.015023},"volumeRatio":1.2956628172956792,"impliedVol":0.7487,"impliedVolPercentile":0.1365},"requestUrl":"/m/hq/s/NKTR/wiki","defaultTab":"wiki","newsList":[{"id":"2614307748","title":"Nektar Therapeutics Schedules Fourth-Quarter and Full-Year Financial Results Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2614307748","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614307748?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:00","pubTimestamp":1772146822,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Schedules Fourth-Quarter and Full-Year Financial Results Call               Nektar Therapeutics will announce its fourth-quarter and full-year 2025 financial results on Thursday, M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL9HqgZf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2614729715","title":"Nektar Therapeutics to Present at TD Cowen Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614729715","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614729715?lang=en_us&edition=fundamental","pubTime":"2026-02-25 07:00","pubTimestamp":1771974018,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics to Present at TD Cowen Annual Health Care Conference               Nektar Therapeutics said its management will participate in the TD Cowen 46th Annual Health Care Conference in Bo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL87bPNl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVT.AU","BK7035","NKTR","BK4007"],"gpt_icon":0},{"id":"2613334717","title":"A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2613334717","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613334717?lang=en_us&edition=fundamental","pubTime":"2026-02-23 23:20","pubTimestamp":1771860034,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) shares are back in focus after the company announced a research collaboration with the University of California, San Francisco and MS expert Dr. Stephen Hauser to study its TNFR2 agonist antibody NKTR-0165.\nSee our latest analysis for Nektar Therapeutics.\nThe UCSF collaboration headlines a very strong run for Nektar, with a 30 day share price return of 98.68% and a year to date share price return of 69.81%. The one year total shareholder return is very large, and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-new-ucsf","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-new-ucsf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2613578732","title":"B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2613578732","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613578732?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:40","pubTimestamp":1771854007,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $129.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"gpt_icon":0},{"id":"2612045162","title":"Nektar Therapeutics Partners with UCSF to Study MS Antibody Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2612045162","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612045162?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:03","pubTimestamp":1771329835,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics has announced a research collaboration with the University of California, San Francisco  and Dr. Stephen Hauser to study the potential of NKTR-0165, a TNFR2 agonist antibody, in reducing neurodegeneration and promoting neuroprotection in multiple sclerosis. Under the agreement, UCSF will conduct and fund the research, while Nektar will supply the investigational antibody and retain all program rights.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL9Mfbjz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2612848451","title":"Nektar Therapeutics Announces Research Collaboration With Ucsf and DR. Stephen Hauser for Nktr-0165, a Tumor Necrosis Factor Receptor 2 (Tnfr2) Antibody, in Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2612848451","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612848451?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA2HPN6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2611193070","title":"Nektar Therapeutics Closes $460 Million Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193070","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193070?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:39","pubTimestamp":1771018741,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  closed its public offering of almost 7.64 million shares, raising $460 million.The offering included 1.03 million shares sold to underwriters exercising their option to purchase additional stock, as well as 293,103 prefunded warrants, the company said Friday in a statement.The stock was sold at $58 a share.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQR","BK4215","BK4585","BK4588","NKTR","BK4007"],"gpt_icon":0},{"id":"2611971892","title":"BUZZ-U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln National","url":"https://stock-news.laohu8.com/highlight/detail?id=2611971892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611971892?lang=en_us&edition=fundamental","pubTime":"2026-02-13 02:36","pubTimestamp":1770921398,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-FedEx Corp, Lincoln NationalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL6N3Z80QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","IRM","ODFL","BRO","AMAT","NEM","OGN","HWM","FDX","PBF","PPG","CBRE","IFF","NTST","PCG","HL","WST","LNC","PAYC","BAX","TRIP","ZTS","ICLR","ZBRA","BTU","NRGV","SPHR","TEX","ALB","CDE","BBIO","CSCO","BRKR","KMX","HPQ","VKTX","ANGI","SCCO","AEP","HNRG","ROL","UTZ","HCC","CGNX","DELL","CROX"],"gpt_icon":1},{"id":"2610529922","title":"BUZZ-Nektar Therapeutics eases after boosted $400 mln share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2610529922","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610529922?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:17","pubTimestamp":1770905845,"startTime":"0","endTime":"0","summary":"** Nektar Therapeutics NKTR.O shares down 5.6% premarket to $62.63 after raising more equity than planned. ** San Francisco, California-based firm late Weds sold ~6.9 mln shares, including 293,103 pre-funded warrants, at $58 for $400 mln gross proceeds. ** Offering size increased from $300 mln; prices at 12.6% discount to stock's last close. ** NKTR shares surged 51% on Tues after co earlier in the day said its eczema drug, rezpegaldesleukin, showed year-long benefit. ** Stock jumped another 18% on Weds to notch its highest close since Aug 2022. ** NKTR intends to use net offering proceeds for general corp purposes, including R&D, clinical development and Phase 3 trials for rezpegaldesleukin. ** Jefferies, TD Cowen and Piper Sandler joint bookrunners. ** Through Weds close, NKTR shares up 57% YTD; they closed at $10.96 a year ago. ** 7 of 8 analysts rate stock \"strong buy\" or \"buy\", 1 \"hold\"; median PT $115, per LSEG data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL6N3Z80Z9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","BK4007","NKTR","LU0053671581.USD","PIPR","BK4127","JEF"],"gpt_icon":0},{"id":"2610996994","title":"BRIEF-Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2610996994","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610996994?lang=en_us&edition=fundamental","pubTime":"2026-02-12 11:25","pubTimestamp":1770866714,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public OfferingFeb 11 (Reuters) - Nektar Therapeutics NKTR.O:NEKTAR THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $400 MILLION PUBLIC OF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8M2YLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2610994995","title":"Nektar Therapeutics - Shares Sold at $58.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610994995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610994995?lang=en_us&edition=fundamental","pubTime":"2026-02-12 11:24","pubTimestamp":1770866641,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA8M2YLJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2610951114","title":"BUZZ-Nektar extends surge after promising eczema drug data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610951114","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610951114?lang=en_us&edition=fundamental","pubTime":"2026-02-11 23:43","pubTimestamp":1770824612,"startTime":"0","endTime":"0","summary":"** Nektar Therapeutics NKTR.O shares up 14.9% to $64.33, over two-month high on Weds, adding to big gain in prior session after its eczema drug showed promise. ** NKTR shares surged 51% on Tues after co earlier in the day said rezpegaldesleukin showed year-long benefit. ** After the bell Tues, NKTR commenced $300 mln offering consisting of stock and pre-funded warrants in part to fund. ** Jefferies, TD Cowen and Piper Sandler joint bookrunners. ** BTIG on Tues said after the data NKTR remains one of its 1H26 top picks and hiked its PT from $118 to $151. ** 7 of 8 analysts rate stock \"strong buy\" or \"buy\", 1 \"hold\"; median PT $115, per LSEG data. ** With the move on Weds, NKTR shares up more than six-fold over the past 12 months","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","PIPR","BK4559","BK4127","BK4007","JEF","NKTR"],"gpt_icon":0},{"id":"2610817669","title":"U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2610817669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610817669?lang=en_us&edition=fundamental","pubTime":"2026-02-11 16:12","pubTimestamp":1770797522,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, WalmartFeb 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, Rapid7","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","WCC","KVYO","PANW","LU1221951046.USD","CAH","DGX","HNGE","MEDP","FISV","LU2108987350.USD","MAS","LU1201861165.SGD","LU0738911758.USD","EVMN","LU0154245756.USD","RDN","AEIS","NKTR","HAS","PRCH","BLKB","BL","RPD","WMB","ACM","LU1621767737.EUR","ECL","MAT","NET","ICHR","MAR","GILD","INCY","LYFT","DD","LU1670710588.SGD","FTV","ALL","EW","UPST","COTY","LU0320765646.SGD","WMT","KO","LSCC","PROK","DDOG","SAIA"],"gpt_icon":0},{"id":"2610602168","title":"Nektar Therapeutics : Btig Raises Target Price to $151 From $118","url":"https://stock-news.laohu8.com/highlight/detail?id=2610602168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610602168?lang=en_us&edition=fundamental","pubTime":"2026-02-11 12:40","pubTimestamp":1770784807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2610761946","title":"Nektar Therapeutics Launches $300 Million Public Offering with Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2610761946","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610761946?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:09","pubTimestamp":1770757781,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics announced the commencement of an underwritten public offering of $300 million of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares and pre-funded warrants in the offering are being offered by Nektar. The company also intends to grant underwriters a 30-day option to purchase up to an additional $45 million of shares. Net proceeds from the offering will be used for general corporate purposes, including research and clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL4gHLv8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2610765156","title":"Nektar Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2610765156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610765156?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:05","pubTimestamp":1770757501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUA3VYKMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2610676639","title":"Nektar Therapeutics - Announces $300 Mln Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2610676639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610676639?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:05","pubTimestamp":1770757501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUA3VYKMR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2610862069","title":"Nektar Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2610862069","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610862069?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:55","pubTimestamp":1770746100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 12:55 ET (17:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2610203806","title":"Nektar price target raised to $151 from $118 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2610203806","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610203806?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:20","pubTimestamp":1770744014,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Nektar (NKTR) to $151 from $118 and keeps a Buy rating on the shares. The stock remains one of the firm’s 1H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-price-target-raised-to-151-from-118-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-price-target-raised-to-151-from-118-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2610162211","title":"Nektar upgraded to Outperform from Market Perform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2610162211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610162211?lang=en_us&edition=fundamental","pubTime":"2026-02-11 00:30","pubTimestamp":1770741034,"startTime":"0","endTime":"0","summary":"William Blair upgraded Nektar (NKTR) to Outperform from Market Perform. Published first on TheFly – the ultimate source for real-time, market-movin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-upgraded-to-outperform-from-market-perform-at-william-blair-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-upgraded-to-outperform-from-market-perform-at-william-blair-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.1078},{"period":"1month","weight":0.7328},{"period":"3month","weight":0.0106},{"period":"6month","weight":1.207},{"period":"1year","weight":4.6318},{"period":"ytd","weight":0.5587}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.026909},{"month":3,"riseRate":0.387097,"avgChangeRate":-0.002052},{"month":4,"riseRate":0.451613,"avgChangeRate":0.01158},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction